

RÉSUMÉ DIGEST

ACT 832 (HB 761)

2026 Regular Session

Hilferty

Existing law establishes an advisory board within the Department of Insurance to review and provide medical recommendations on the approval of novel treatments for rare cancers.

Existing law delineates the board's composition, consisting of 15 members, mandates quarterly public meetings unless otherwise specified, and requires the submission of written reports to the legislature within 30 days following each meeting.

New law retains the provisions of the existing law while revising the advisory board's composition and reporting requirements. New law expands the membership of the advisory board from 15 to 17 members and increases the number of oncologists specializing in the treatment of rare cancers from two to four.

New law removes the executive director of Taking Aim at Cancer in Louisiana from the board and substitutes this position with the executive director of the Cancer Association of Louisiana.

While the requirement for quarterly public meetings remains, new law extends the deadline for the submission of written reports from 30 days to no later than 45 days following each meeting.

New law explicitly stipulates that such reports shall be submitted to the House Committee on Insurance and the Senate Committee on Insurance, rather than the legislature at large.

New law authorizes the commissioner to promulgate rules and regulations in accordance with the Administrative Procedure Act, as necessary to implement the provisions governing the advisory board.

Effective upon signature of governor (June 8, 2026).

(Amends R.S. 22:1076.1)